EUFEPS
Conference on
Optimising Drug Development
together with
European Biosimulation Network of Excellence:
Biosimulation - A New Tool in Drug Development
Effective
Integration of Systems Biology, Biomarkers, Biosimulation and Modelling
in Streamlining Drug Development
A
Unique Discussion Forum for Scientists from the Pharmaceutical Industry,
Regulatory Agencies and Academic Institutions
November
29 - December 1 • 2006 •
Basel Convention Center • Basel
• Switzerland
Organised
by the European
Federation for Pharmaceutical Sciences (EUFEPS) and the European
Biosimulation Network of Excellence (BioSim)
Co-sponsored by the American College of Clinical Pharmacology
(ACCP), the European Center for Pharmaceutical Medicine (ECPM),
and the Swiss Society of Pharmaceutical Sciences (SGPhW)
The Conference opens
on Wednesday, November 29, 2006, at 08:15 (Pre-registration on Tuesday,
November 28) and it closes on Friday, December 1, at 14.15.
Scope
and Aim
To increase the efficiency and productivity of new drug development,
new tools for predictive human models of disease and efficient drug
discovery, development and evaluation are necessary. Among these
new technologies, “modelling”, “biomarkers”,
“biosimulation“ and “systems biology” are
gaining increasing attention. The aim of this Conference is to present
and discuss both visionary and effective integration of them all,
also to develop a foundation for further research, development and
utilisation of them.
For example, modelling is applied in drug development to predict
the outcome of the next steps to be taken in various processes.
Biomarkers will enable translational data from preclinical species
to humans, hence helping to understand drug effects, side effects
and toxicity in a more predictive manner. Quality in data is a must
for successful submission to regulatory authorities, arrived at
by careful study design and validation. Biosimulation is, furthermore,
an old dream of in silico pharmaceutical sciences. Core
activities would include translation of experimental insights into
consistent mathematical frameworks, including formal models to predict
the course of physiological processes under varying conditions.
Systems biology approaches are expected to link genomic, proteomic
and metabolomic data and bioinformatics, to provide better understanding
and simulation of function and dysfunction of living systems. New
insights will change paradigms of drug discovery, development and
evaluation.
The Conference is intended for drug discoverers, developers and
evaluators, including in silico, in vitro and in vivo
scientists, clinical pharmacologists and other scientists exploiting
modelling, biomarkers, biosimulation and systems biology, as well
as for academic researchers who want better insight into industry
use of these approaches, e.g. to become aware of urgent training
needs, and for regulator and patient group scientists evaluating
today’s and tomorrow’s medicines therapy.
Sessions
will include
-
Model-Based
Drug Development (I):
Role of Systems Biology in Drug Discovery
- Model-Based Drug
Development (II): Pharmacokinetic/Pharmacodynamic Principles in
Preclinical Development
- Model-Based Drug
Development (III):
Case studies in Drug Discovery & Preclinical Development
- Model-Based Drug
Development (IV):
Modelling & Simulation in Clinical Development – The
Concept
- Model-Based Drug
Development and Biomarkers (I):
Case Studies in Clinical Development
- Model-Based Drug
Development and Biomarkers (II):
Clinical Trial Designs and Statistical Aspects
- Learning from failures:
Could biomarkers and model-based drug development have prevented
phase III failures?
- Implementation of
Systems Biology, Biomarkers, Biosimulation and Modelling in Pharmaceutical
Industry: Current Status and Lessons Learned
Format
& Preliminary Programme
Using a similar format to previous EUFEPS conferences, key segments
of the process are broken down into a number of sessions, each with
lectures and discussions and general discussion sessions for conclusions
and recommendations.
Scientific
& Planning Committee
Ole J Bjerrum, Copenhagen DK, Fritz R Bühler,
Basel CH, Anne Marie Clemensen, Lyngby DK, Meindert
Danhof, Leiden NL, Hartmut Derendorf, Gainesville
FL USA, Igor Goryanin, Edinburgh UK, Rajesh Krishna,
Rahway NJ USA (Co-Chair), Lawrence J Lesko, Silver
Spring MD USA, Hans H Lindén, Stockholm SE, Erik
Mosekilde, Lyngby DK (Co-Chair), Christian R Noe, Vienna
AT, Carl Peck, Washington DC USA, Ian C Ragan, Windlesham
UK, Shashank Rohatagi, Bridgewater NJ USA, Malcolm
Rowland, Manchester UK, Hans Günter Schäfer,
Biberach An Der Riss DE (Co- Chair), Donald R Stanski,
Basel CH, Steffen Thirstrup, Copenhagen DK, Hans Westerhoff,
Amsterdam NL, Michael Zühlsdorf, Wuppertal DE
Exhibition
Information
Companies are welcome to participate as an exhibitor at this Conference.
The Conference delegates are academics, industrialists, regulators
and students which will give you a unique opportunity to meet experts
in your field. The exhibition offers every opportunity to promote
and position your company, your products, your services, your expertise
and your specialists, facilitating your contact with them, predicting
their needs and shaping future collaboration.
Exhibition
Organiser

Health Links has
been contracted as the Exhibition Organiser.
Please direct inquiries regarding exhibition or sponsorship to Health
Links (channey@health-links.co.uk),
Windsor House, 11A High Street Kings Heath, Birmingham B14 7BB,
United Kingdom, Tel +44 208 7496471, Fax +44 121 2483390, www.health-links.co.uk
How to apply
Application for stand space must be made on the “Application
and Contract” form. Every effort will be made to accommodate
exhibitors request for space and position. The exhibition stands
and space are assigned on a “first come – first served”
basis.
Click for Application
and Contract Form.
Sponsorship
Opportunities
To sponsor this Conference and by this enable additional quality
meetings on key topics, contact the Exhibition Organiser Health
Links (channey@health-links.co.uk)
or the EUFEPS Executive Director, Hans H Lindén (hans.linden@eufeps.org).
Please direct general questions about the conference to the Conference
Secretariat (conferences@eufeps.org).
Oral
and poster contributions
Scientific contributions relating to the scope and aim of the Conference
will be welcome and considered for poster presentations. Abstracts
should be submitted to the EUFEPS Secretariat, both as an email
attachment and as a hard copy. Submission deadline is October
31, 2006.
Click for Editorial
Instructions.
Language
English will be the language of the Conference. No simultaneous
translation will be provided.
Organiser
EUFEPS was founded in 1991. Its mission is to advance excellence
in the pharmaceutical sciences and innovative drug research, and
to represent the interests of scientists engaged in drug research
and development, drug regulation and drug policymaking. Currently,
it links scientific societies and associations in 24 European countries
and there are more than 600 individual members of EUFEPS.
Basel
Basel beats differently is the motto with which Basel wants to draw
attention to itself at home and abroad. Special to Basel in fact
different is its position in the so-called Dreiländereck, the
triangle formed by the three countries of Switzerland, Germany,
and France. Basel is known as an open, many-faceted cultural, educational,
and economic metropolis. Basel is the centre of northwestern Switzerland,
on the border with Germany and France, located at the very core
of central Europe. Both its historic townscape and modern architecture
are part of Basel’s living present. The choice of leisure
facilities available in Basel is much greater than in other town
of similar size. This is true not only because of its above-average
cultural range, its many high-class museums such as its Kunstmuseum
(Museum of Fine Arts), the Beyeler Foundation, or the Antikenmuseum
(Museum of Antiquities). Besides culture, Basel also offers many
other possibilities for amusing oneself: at sports, walking through
the old town, or a stroll to the shops in the inner city. The Basel
region also offers many opportunities for enjoying one’s leisure
hours. There are many of these, in the parks, the green-belt areas
around the city, its rivers, and the nearby recreational areas in
the adjacent more rural halfcanton, in the Black Forest, and in
Alsace.
Final
Programme
Day 1 – Wednesday,
November 29, 2006
| 08:15 |
Welcome
to the Conference and Introduction to the Programme
Christian R Noe, University of Vienna and EUFEPS President,
Vienna AT
Hans Günter Schäfer, Conference Co-Chair,
Boehringer-Ingelheim, Biberach An Der Riss DE |
| 08:35-09:35 |
Keynote
Session
Co-Chairs
Christian R Noe, University of Vienna, Vienna AT
Hans Günter Schäfer, Boehringer-Ingelheim,
Biberach An Der Riss DE |
| 08:35
|
Innovative
Medicines Initiative (IMI): Focus, challenges and impact on
drug discovery and development
Ian C Ragan, Eli Lilly, Windlesham UK |
| 09:05 |
Role
of biosimulation and European BioSim Network in drug research
and development
Erik Mosekilde, Danish Technical University, Lyngby
DK |
| 09:35-12:25
|
Session
I: Model-based drug development (I): Role of systems
biology in drug discovery
Co-Chairs
Igor Goryanin, Edinburgh Centre for Bioinformatics,
Edinburgh UK
Erik Mosekilde, Danish Technical University, Lyngby
DK |
| 09:35 |
Integrating
systems biology in the drug discovery process: Organisational
and practical issues
Klaus Prank, GlaxoSmithKline, Stevenage UK |
| 10:10 |
Coffee/Tea |
| 10:40 |
Biosimulation
for drug discovery and drug safety
Oleg Demin, Moscow State University, Moscow RU |
| 11:15 |
Model
of Krebs Cycle: Impact on drug safety
Igor Goryanin, Edinburgh Centre for Bioinformatics,
Edinburgh UK |
| 11:50
|
Virtual
heart and modelling of the physiological mechanisms of QT prolongations
Denis Noble, University of Oxford, Oxford UK |
| 12:25
|
Lunch
|
| 13:45-15:30
|
Session
II: Model-based drug development (II): Pharmacokinetic/pharmacodynamic
principles in preclinical development
Co-Chairs
Carl C Peck, Center for Drug Development Science, Washington
DC USA
Malcolm Rowland, University of Manchester, Manchester
UK |
| 13:45
|
In
silico ADMET: Current status and future directions
David E Clark, Argenta Discovery, Harlow UK |
| 14:20 |
Physiological-based
pharmacokinetic modelling: Opportunities and limitations
Malcolm Rowland, University of Manchester, Manchester
UK |
| 14:55
|
Pharmacokinetic/pharmacodynamic
modelling: Current concepts
Hartmut Derendorf, University of Florida, Gainesville
FL USA |
| 15:30-18:15 |
Session
III: Model-based drug development (III): Case studies
in drug discovery & preclinical development
Co-Chairs
Ole J Bjerrum, Danish University of Pharmaceutical
Sciences, Copenhagen DK
Ian C Ragan, Eli Lilly, Windlesham UK |
| 15:30 |
Biosimulation
of critical pathways in diabetes: Are we using the best biomarkers?
Morten Colding-Jørgensen, Novo Nordisk, Maaloev
DK |
| 16:05 |
Coffee/Tea |
| 16:30 |
Models
are to be used, not believed: Case studies from modelling and
simulation in glucose-insulin regulation and diabetes
Paolo Vicini, University of Washington, Seattle WA
USA |
| 17:05 |
Tumour growth models in oncology – purpose, limitations
and future perspectives
Bernd Müller-Beckmann, Roche Diagnostics, Penzberg
DE |
| 17:40
|
Using
tumour growth animal models in mechanistic PK/PD models to understand
dose response
Iñaki F Trocóniz, University of Navarra,
Navarra ES |
| 18:15
|
Panel
Discussion on Sessions I-III |
| 19:15
|
Reception
Buffet |
Day
2 – Thursday, November 30, 2006
| 08:15 |
Welcome
to the Second-day programme
Rajesh Krishna, Conference Co-Chair, Merck & Co, Rahway
NJ USA |
| 08:30-10:15 |
Session
IV: Model-based drug development (IV): Modelling &
simulation in clinical development – The concept
Co-Chairs
Rajesh Krishna, Merck & Co, Rahway NJ USA
Christian R Noe, University of Vienna, Vienna AT |
| 08:30
|
Generating
causal evidence for linking biomarkers with clinical endpoints
Carl C Peck, Center for Drug Development Science, Washington
DC USA |
| 09:05
|
Strategic
modelling and simulation: How does it facilitate decision making
in drug development
Marc Pfister, Bristol-Myers Squibb, Princeton NJ USA |
| 09:40-12:30
|
Session
V: Model-based drug development and biomarkers (I): Case
studies in clinical development
Co-Chairs
Steffen Thirstrup, Danish Medicines Agency, Copenhagen
DK
Michael Zühlsdorf, Bayer, Wuppertal DE |
| 09:40
|
Resisting
population PK – The story of P-gp inhibition and Co-administered
chemotherapy
Dinesh de Alwis, Eli Lilly, Windlesham Surrey UK |
| 10:15 |
Coffee/Tea |
| 10:45
|
Biosimulation
and cancer chronotherapy
Albert Goldbeter, University of Brussels, Brussels
BE |
| 11:20
|
Biomarkers
for Alzheimer’s disease
Lars Sundström, InnoMed Research Project, Southampton
Hants UK |
| 11:55
|
Disease
modelling and biomarker in Alzheimer’s disease
Peter A Lockwood, Pfizer, Ann Arbor MI USA |
| 12:30 |
Lunch
|
| 13:35-15:45 |
Session
VI: Model-based drug development and biomarkers (II):
Clinical trial designs and statistical aspects
Co-Chairs
Fritz Bühler, University of Basel, Basel CH
Joga Gobburu, FDA, Silver Springs MD USA |
| 13:35
|
Using
biomarkers for adaptive clinical trial design: Concept and application
Rajesh Krishna, Merck & Co, Rahway NJ USA |
| 14:10
|
Evaluating
biomarkers as surrogate markers
Ariel Alonso, Hasselt University, Diepenbeek BE |
| 14:45
|
Regulatory
impact of modelling and simulations
Joga Gobburu, FDA, Silver Spring MD USA |
| 15:15
|
A
critical path opportunity: Biomarkers and model-based drug development
– What should they deliver?
Robert Powell, FDA, Silver Spring MD USA |
| 15:45 |
Coffee/Tea |
| 16:20-17:30 |
Session
VII: Learning from failures: Could biomarkers and model-based
drug development have prevented phase III failures?
Co-Chairs
Peter A Lockwood, Pfizer, Ann Arbor MI USA
Joga Gobburu, FDA, Rockville MD USA |
| 16:20 |
Biomarkers
to prevent late phase failures
Richard Peck, Eli Lilly, Surrey UK |
| 16:55 |
Preventing, recovering and learning from phase III failures
using modelling and simulation
Colin Pillai, Novartis, Basel CH |
| 17:30
|
General
Discussion of
Session IV-VII |
| 18:30
|
Drinks
and Snacks |
Day
3 – Friday, December 1, 2006
| 08:30 |
Welcome
to the Third-day programme
Co-Chair
Erik Mosekilde, Conference Co-Chair, Danish Technical
University, Lyngby DK |
| 08:45-12:45 |
Session
VIII: Implementation of systems biology, biomarkers,
biosimulation and modelling in pharmaceutical industry: Current
status and lessons learned
Co-Chairs
Colin Pillai, Novartis, Basel CH
Lars Sundström, InnoMed Research Project, Southampton
Hants UK |
| 08:45 |
Signalling
drugs vis-à-vis phosphorylation cascades
Hans Victor Westerhoff, Vrije Universiteit Amsterdam,
Amsterdam NL |
| 09:20 |
Systems
biology: A new hope for drug discovery?
Adriano M Henney, AstraZeneca, Macclesfield UK |
| 09:55 |
Biomarkers
and drug discovery and development: ‘The Roche Experience’
Klaus Lindpaintner, F Hoffmann–La Roche, Basel
CH |
| 10:30 |
Integration
of M&S in clinical drug development: General aspects and
the Boehringer-Ingelheim Experience
Alexander Staab, Boehringer-Ingelheim, Biberach An
Der Riss DE |
| 11:05 |
Coffee/Tea |
| 11:30 |
Integration
of pharmacogenomics in clinical drug development: General aspects
and the GlaxoSmithKline Experience
Colin Spraggs, GlaxoSmithKline, Research Triangle Park
NC USA |
| 12:05 |
Implementing
biomarker strategies and today’s enabling technologies:
The organisational challenge
John C Bloom, Eli Lilly, Indianapolis IN USA |
| 12:40 |
Panel
Discussion, Conclusions and Recommendations
Co-Chairs
Rajesh Krishna, Merck & Co, Rahway NJ USA
Erik Mosekilde, Danish Technical University, Lyngby
DK
Hans Günter Schäfer, Boehringer-Ingelheim,
Biberach An Der Riss DE |
| 13:30 |
Closing
remarks
Christian R Noe, University of Vienna and EUFEPS President,
Vienna AT |
Location
The
Conference will take place at the Basel Convention Center, Messeplatz
21, CH-4021 Basel, Switzerland. Tel +41 58 2002020; Fax +41 58 2062186
How
to get there
from
the Airport:
-
Taxi, travelling time around 15 minutes at an approximate cost
of CHF 40,-
-
Airport coach to the Railway station SBB where you embark the
tram no 2 in the direction City. Stop ‘Messeplatz’.
Travelling time from airport approximately 40 minutes, cost around
CHF 3,-
from
the Badischer Bahnhof (Railway station):
-
Tram no 2 or 6, direction City. Stop ‘Messeplatz’.
Travelling time around 5 minutes. Cost approximately CHF 2,-
-
Taxi 3 minutes at an approximately cost of CHF 10,-
from the Schweizer Bahnhof SBB (Railway station):
-
Tram no 2, direction City. Stop ‘Messeplatz’. Travelling
time around 12 minutes. Cost approximately CHF 3,-
-
Taxi travelling time around 8 minutes at a cost of around CHF
20,-
Registration
The
registration fee (EUFEPS Membership 10% reduction) includes all
conference documentation, all coffee breaks, three lunches and one
reception buffet. The cost for hotel accommodation and travel is
not included in the registration fee.
Click for online
registration
Click for Registration
Form (PDF)
Conference
Registration Fees
(CHF)
(Incl VAT 7,6 %)
|
EUFEPS |
EUFEPS
|
EUFEPS
|
EUFEPS |
Members
before
October 31,
2006
|
Non-
Members before
October 31,
2006
|
Members
after
October 31,
2006
|
Non-
Members after
October 31,
2006 |
Industrial
delegate
|
1880
|
2090
|
2310
|
2575 |
Academy
delegate
|
1018
|
1130
|
1330
|
1480 |
Government
delegate
|
1018
|
1130
|
1330
|
1480 |
Student
delegate
|
475
|
530
|
550
|
615 |
EUR
1 = CHF 1.5 Students
Participants applying for student fees should include proof of their
student status (a photocopy of the university identity card).
Confirmation
In order to receive confirmation of registration by email, please
make sure to indicate the email address on the registration form!
Confirmation will be sent upon receipt of payment.
Alterations
Alterations to your registration must be made in writing and sent
to Congrex Sweden AB by email or fax.
Inquiries
Congrex Sweden AB has been contracted for registration and administration
support. Please direct all inquiries regarding registration, accommodation
or payment to Congrex at: codd.registration@congrex.com
Tel +46 8 459 66 00
Fax +46 8 661 91 25
Hotel
Reservation
Hotel reservations can be made on-line or on the attached hotel
registration form. A number of hotel rooms have been reserved at
hotels at preferential rates for the Conference. The hotels are
both situated in the city centre of Basel and near the Conference
venue. The Conference venue is accessible with public transportation
or by foot depending on choice of hotel. The rates below are
per room, per night, including breakfast, city tax and VAT (7,6
%).
Hotel accommodation will be reserved and confirmed only when Congrex
Sweden AB has received your credit card number as a guarantee on
the registration form. Congrex Sweden AB reserves the right to book
another hotel if the desired accommodation should be fully booked.
To ensure that the hotel reservation will be made as required, please
indicate your credit card number on the registration form. After
October 31, 2006, accommodation and rates will be confirmed according
to availability.
The hotel reserves the right to charge you for all nights reserved
and guaranteed on the registration form, should you check out before
confirmed departure date or in case of no-show.
All reservations are handled by Congrex Sweden AB. Possible changes
of your hotel reservation as well as cancellation must be made in
writing to Congrex Sweden AB. Please do not contact the hotel directly.
| Hotel
Rates |
| Category |
CHF
Single room |
CHF
Double room |
CHF
Breakfast |
Rate
available
until |
Ramada
Plaza Basel
|
264 |
294 |
included |
October
31, 2006 |
Novotel
Basel
|
224 |
248 |
included |
October
31, 2006 |
Der
Teufelhof
|
220 |
295 |
included |
October
31, 2006 |
| Spalentor
Basel |
149 |
194 |
included |
October
31, 2006 |
Payment
Registration Fee and Hotel Accommodation
Please indicate your name and the payment reference number
0666 on all money transfers.
Congrex Sweden AB will not be responsible for identifying funds
transferred directly into the account when the name of the participant
or invoice number is not mentioned, nor will Congrex Sweden AB accept
charges of bank fees associated with the transfer.
Payment
should be made in advance by one of the following methods
- American Express,
Visa or Eurocard/Mastercard may be used for all charges.
Please indicate card number and expiry date on the registration
form.
- Transfer to SEB (Skandinaviska
Enskilda Banken), SE-106 40 Stockholm, Sweden, BIC/SWIFT-code:
ESSESESS, Account no. 5501-8248858, IBAN No SE75 5000 0000 0550
1824 8858 in CHF to Congrex Sweden AB.
- Banker’s draft,
which should be sent together with the registration form by ordinary
mail. The Banker’s draft should be purchased at your bank
and made out in CHF to Congrex Sweden AB, Attn: CODD. Please cross
the draft. We are not able to accept personal cheques, company
cheques or Eurocheques. Please send the Banker’s draft to:
Congrex Sweden AB, Attn: CODD, P.O. Box 5619, SE-114 86 Stockholm,
Sweden.
- Scandinavian residents
may pay by bank or postal giro transfer. Bank giro 224-7021, or
Postal giro 9052-2.
As from 3 weeks before
the Conference we only accept credit card as payment. Registrations
will be confirmed when Congrex Sweden AB has received payment. Admission
to the Conference is granted only if Congrex Sweden AB has received
the registration fee. Delegates, who have made late payments, should
bring a proof of payment to the Conference. Failure to produce this
on request gives Congrex Sweden AB the right to charge the amount
to your credit card. Kindly note that Congrex Sweden AB only require
payment forthe registration fee. Participants need to provide Congrex
Sweden AB with a credit card number to guarantee the accommodation
but the payment for the stay will be charged directly by the hotel
upon check-out.
Cancellation
of Registration
Notification of cancellation must be made in writing and sent to
Congrex Sweden AB. Cancellation of registration will be accepted
until October 31, 2006, up to which date the total amount will be
refunded less CHF 80 for administrative expenses. For cancellations
made after October 31, 2006, we regret that no refunds can be made.
Cancellation
of Hotel Reservation
Notification of cancellation must be made in writing and sent to
Congrex Sweden AB. Cancellation of any hotel reservation will be
accepted until October 31, 2006, up to which date the hotel deposit
will be refunded less an administration fee of CHF 80. We regret
that after October 31, 2006, we will charge you for the whole stay.
General
Information
Badges
Each participant will receive a name badge upon registration. For
security reasons all participants are requested to wear their name
badge during all the Conference activities.
Currency
The currency in Basel is CHF (EUR 1 is equal to approx. CHF 1.5).
Disclaimer/Liability
The Organising Committee and Congrex Sweden AB accept no liability
for any injuries/losses incurred by participants and/or accompanying
persons, nor loss of, or damage to, any luggage and/or personal
belongings.

The Congrex Group works internationally with subsidiaries in the
Netherlands, the United States and Sweden as well as licensed partners
throughout Europe and Latin America.
Useful
Adresses
Conference
Registration
Congrex Sweden AB
Attn: CODD
PO Box 5619
SE-114 86 Stockholm, Sweden
Tel +46 8 4596600
Fax +46 8 6619125
Email codd.registration@congrex.com
Website www.congrex.com |
EUFEPS
Secretariat
Attn. Annika Nyman
PO Box 1136
SE-111 81 Stockholm, Sweden
Phone +46 8 7235000
Fax +46 8 4113217
Email conferences@eufeps.org |
Hotel
Reservation
Congrex Sweden AB
Attn: CODD
PO Box 5619
SE-114 86 Stockholm, Sweden
Tel +46 8 4596600
Fax +46 8 6619125
Email codd.registration@congrex.com
Website www.congrex.com |
Conference
Venue
Basel Convention Center
Messeplatz 21
CH-4021 Basel, Switzerland
Tel +41 58 2002020
Fax +41 58 2062186
Website www.messe.ch |
Conference
Exhibition
Health Links
Attn. Mr Chris Hanney
Windsor House, 11A High Street
Kings Heath, Birmingham B14 7BB
United Kingdom
Phone +44 208 7496471
Fax +44 121 2483390
Email channey@health-links.co.uk
Website
www.health-links.co.uk |
|

|